InMed Pharmaceuticals (INM) Change in Receivables (2019 - 2025)
InMed Pharmaceuticals' (INM) quarterly Change in Receivables came in at -$159977.0 in Q4 2025, down 606.46% year-on-year from $31587.5 in Q4 2024, and down 30.96% quarter-over-quarter from -$122160.0 in Q3 2025.
InMed Pharmaceuticals (INM) Change in Receivables (2019 - 2025) Analysis & Trends
InMed Pharmaceuticals' Change in Receivables history runs 7 years deep, the most recent figure standing at -$159977.0 for Q4 2025.
- On a quarterly basis, Change in Receivables fell 606.46% year-over-year to -$159977.0 in Q4 2025; TTM through Dec 2025 was -$77178.0, a 30.03% increase from a year earlier, with the FY2025 full-year figure at $114690.0, up 24.07% from the prior year.
- Change in Receivables fell to -$159977.0 in Q4 2025 per INM's latest filing, from -$122160.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $207019.0 in Q4 2023 and bottomed at -$165188.0 in Q1 2024.
- The 5-year median for Change in Receivables is $1142.5 (2021), against an average of $2061.0.
- Biggest YoY gain for Change in Receivables was 14451.57% in 2022; the steepest drop was 2592.58% in 2022.
- Year by year, Change in Receivables stood at -$638.0 in 2021, then jumped by 14451.57% to $91563.0 in 2022, then surged by 126.09% to $207019.0 in 2023, then sank by 110.94% to -$22645.0 in 2024, then slumped by 606.46% to -$159977.0 in 2025.
- Per Business Quant, the three latest INM Change in Receivables figures stand at -$159977.0 (Q4 2025), -$122160.0 (Q3 2025), and $99715.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -159,977.00 |
| Dec 31, 2025 | -159,977.00 |
| Sep 30, 2025 | -122,160.00 |
| Sep 30, 2025 | -122,160.00 |
| Jun 30, 2025 | 99,715.00 |
| Jun 30, 2025 | 99,715.00 |
| Mar 31, 2025 | 105,244.00 |
| Mar 31, 2025 | 105,244.00 |
| Dec 31, 2024 | -22,645.00 |
| Dec 31, 2024 | -22,645.00 |
| Sep 30, 2024 | -67,624.00 |
| Sep 30, 2024 | -67,624.00 |
| Jun 30, 2024 | 145,157.00 |
| Jun 30, 2024 | 145,157.00 |
| Mar 31, 2024 | -165,188.00 |
| Mar 31, 2024 | -165,188.00 |
| Dec 31, 2023 | 207,019.00 |
| Dec 31, 2023 | 207,019.00 |
| Sep 30, 2023 | -94,549.00 |
| Sep 30, 2023 | -94,549.00 |